Celastrol in cancer therapy: Recent developments, challenges and prospects.

Area of Science:

• Natural Product Chemistry
• Pharmacology
• Oncology

Background:

• Cancer remains a significant global health challenge, necessitating novel therapeutic strategies.
• Natural compounds offer multi-targeting potential and improved safety profiles for drug development.
• Celastrol, derived from Tripterygium wilfordii, is a promising natural compound with demonstrated anti-cancer activities in preclinical research.

Purpose of the Study:

• To review the mechanisms and therapeutic potential of celastrol in various cancers.
• To explore challenges hindering celastrol's clinical translation, including its narrow therapeutic window and poor pharmacokinetics.
• To discuss key pathways affected by celastrol and identify suitable cancer targets for future research.

Main Methods:

• Comprehensive literature review of in vitro and in vivo studies on celastrol's anti-cancer effects.
• Analysis of celastrol's pharmacological activities and mechanisms of action.
• Critical evaluation of factors limiting clinical development and potential solutions.

Main Results:

• Celastrol exhibits significant pharmacological activities against diverse cancer types in preclinical models.
• Key pathways modulated by celastrol have been identified, suggesting specific therapeutic applications.
• Developmental challenges such as poor pharmacokinetic properties and a narrow therapeutic window were highlighted.

Conclusions:

• Celastrol is a promising natural anti-cancer lead compound with significant therapeutic potential.
• Addressing its pharmacokinetic limitations and therapeutic window is crucial for clinical advancement.
• Further research into celastrol derivatives and their druggability is essential for successful clinical translation.